MPアドバイザーからの特別オファー is happy to inform that seven insightful market research studies on pharmaceutical and biotechnology markets prepared by MP Advisors have been added to its catalogue.

Purchased simultaneously, the reports will provide a reader with in-depth understanding of the global pharmaceutical and biotechnology market performance. Besides, we will give a 25% discount to anyone who is willing to buy all reports together.

Each report costs USD 2,000. Please note that the Global Rising Stars Outlook 2015 includes India Rising Stars Outlook 2015 as a part of the report.

A full price of the package is USD 12,000, while the discounted one is USD 9,000.

A list of the research studies included in the offer can be found below.

An independent company with approximately 20 years of experience, MP Advisors is renowned for its unrivalled expertise in exploration of investment opportunities in the field of healthcare.

If you need any additional information or if you would like to acquire the reports, please, contact Alison, our Sales Manager. You can give her a call at +44 208 144 6009 or reach her by Eメール.

Sri Lanka Pharma Market Outlook 2015: More Beyond Importers & Distributors ドル2,000.00

... the healthcare needs of the country. Sri Lanka’s total expenditure on health has increased by ~11%, CAGR (2005-2010), and this has been driven by both private- (+12%) and government ...

Jan、2015 29ページ
Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success ドル2,000.00

All biotech companies - Gilead (GILD), Amgen (AMGN), Biogen Idec (BIIB) and Celgene (CELG), in past year, have given a positive return and hence increased the interest of biotech investors. These companies have been ...

Jan、2015 90ページ
Japan Pharma Outlook 2015: 2015 –Year to Watch Out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives ドル2,000.00

... pricing system adopted in Japan from April -2014 (Annexure 1) is a game changer initiative. It pains most of the companies - whether generic ... Outlook-15, we look deeper into these trends to anticipate likely near term changes of Japanese pharma ... Edoxaban, Lenvatinib, Entyvio, Brintellix, and Ixazomib are the few ...

Jan、2015 153ページ
India Rising Stars Outlook 2015: Traditionally Innovation and Drug Discovery Had Taken a Back Seat in the Indian Pharma Industry with a Few Blips Here and There ドル1,000.00

Traditionally Innovation and drug discovery had taken a back seat in the Indian pharma industry with a few blips here and there. ... 2-3 years thereby rewarding their investors. . In this Outlook we have initiated coverage on Connexios, Bugworks, Cellworks, Tergene and hope that soon we will be able to expand ...

Jan、2015 22ページ
India Pharma Outlook 2015: Accelerating Growth to the Next Level: Moving up the Value Chain Beyond Generics ドル2,000.00

... of NCE/mAb development by Indian companies is a sign of Indian Generics moving up in the chain. Biopharma/ biotech companies in India, S. Korea, China may have significant advantages of low-cost manufacturing ...

2月、2015 109ページ
Global Rising Stars Outlook 2015: Innovative Therapies for Treating Diseases are Being Sought after with Fresh Vigor as New Targets ドル2,000.00

Innovative Therapies for treating diseases ... interested in keeping pace with the development of new medicines. The Regenerative medicine Universe is large and new companies are being ... coverage in our Outlook this year. Key Criteria for Our Selection are:- Uniqueness of the Technology platform and the ability ...

Jan、2015 72ページ
Global Pharma US & EU Outlook 2015: First –In- Class Innovations and Cost Optimization Plays Major Role In Shaping Up Business for Large Cap Pharmaceutical Companies ドル2,000.00

... diabetes (SGLT-2, GLP-1 agonists), Multiple Sclerosis, HCV, melanoma and breast cancer from major ... anti-PD1, anti-PCSK9 and CDK inhibitors have also got exclusive attention by large cap Pharma ... business among major pharma including Vaccines, OTC and animal health to improve margins. Global Pharma continues to ...

Jan、2015 63ページ
G|translate Your license is inactive or expired, please subscribe again!